HOME >> BIOLOGY >> NEWS
Novel antiviral drug concept targets number of human viruses

In laboratory studies, an entirely new approach to antiviral drug development is showing remarkable effectiveness against herpes viruses, a large family of viruses associated with many human diseases. In addition, the innovative strategy targets these viruses at such a fundamental level that it may prove useful against a wide array of other viruses. And because the approach attacks viruses indirectly by making the cells they infect profoundly inhospitable to them, the likelihood that viral drug resistance will develop is thought to be extremely low.

University of Pennsylvania Medical Center researchers reported the findings in a study presented today at the Thirteenth International Conference on Antiviral Research in Baltimore, MD.

"This is a novel approach to the development of antiviral drugs," says Luis M. Schang, Ph.D., a postdoctoral fellow and first author on the study. "In the laboratory, we and others are seeing significant viral inhibition with drugs that have no toxicity to cells. If the strategy shows similar success in animals and, eventually, in humans, it should be applicable against many different kinds of viral infections."

Schang emphasizes that a good deal of work remains to be done before the new approach can be validated as a viable treatment for viral infections in humans.

Until now, antiviral drugs have sought to attack viruses directly by interfering with essential proteins produced by the viruses. Scientists have long known, however, that viruses are parasites and depend on the cells they infect for crucial support of their life cycles. Using the herpes simplex virus (HSV) as model target, the Penn team discovered that by inhibiting a particular set of cellular enzymes upon which the virus depends they can successfully block all viral activity while causing the host cells no ill effects.

"To date, all effective anti-viral drugs target viral proteins because the thought has been that knocking out a cellular
'"/>

Contact: Franklin Hoke
frank.hoke@nasw.org
215-662-2560
University of Pennsylvania School of Medicine
20-Apr-2000


Page: 1 2 3

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2019)... ... January 31, 2019 , ... ... geared toward clinical operations executives and focusing on all facets of clinical trial ... project management, portfolio management, resource management, patient engagement, and more. , “We ...
(Date:1/30/2019)... ... January 30, 2019 , ... ... supports high-growth, high-impact life science and biotechnology companies, announced today that it ... foundations and disease-focused venture funds to discuss their investment philosophies, explain their ...
(Date:1/24/2019)... ... 2019 , ... rHEALTH LLC, an innovative digital health solutions ... United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/682,010, ... application covers the addition of a length scale to hydrogel microparticles. A ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... , ... January 30, 2019 , ... ... from pharma, academia and governmental agencies to discuss best practices for laboratory automation ... February 4-6. , At this year’s conference, Visikol will be at booth ...
(Date:1/24/2019)... ... January 22, 2019 , ... Controlled Contamination Services is ... in the US. Each of these valuable new team members will support its growing ... model moving forward as CCS scales its business. This addition will enable CCS to ...
(Date:1/21/2019)... FRANKLIN, Wis. (PRWEB) , ... January 21, 2019 ... ... company, announced their newest product line, SporActiv™, for the industrial and institutional cleaning ... a variety of residential and commercial cleaning needs. Applications include odor control, floor ...
(Date:1/20/2019)... ... January 17, 2019 , ... Today, Advanced Solutions, Inc., a ... specialized automation technology, titled Automate 3D. Automate 3D, produced by Advanced Solutions, allows ... to deliver to end-users, customers, and ERP systems. , Automate 3D ...
Breaking Biology Technology:
Cached News: